george therapondos, mb chb, frcpc, mph transplant … · from 2008 through 2017 multiple first-line...
TRANSCRIPT
![Page 1: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/1.jpg)
G E O R G E T H E R A P O N D O S , M B C H B , F R C P C , M P H
T R A N S P L A N T H E P A T O L O G Y
O C H S N E R M U L T I O R G A N T R A N S P L A N T I N S T I T U T E
N E W O R L E A N S
Hepatocellular carcinomaNew developments
![Page 2: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/2.jpg)
Disclosures
Advisory boards:
Boston Scientific
Mallinckrodt Pharma
Rebiotix Inc
Speaker’s bureau
Intercept Pharma
Eisai Co.= maker of Lenvatinib
![Page 3: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/3.jpg)
![Page 4: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/4.jpg)
Pembrolizumab
APPROVED!
![Page 5: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/5.jpg)
![Page 6: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/6.jpg)
![Page 7: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/7.jpg)
![Page 8: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/8.jpg)
![Page 9: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/9.jpg)
Currently approved therapies
![Page 10: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/10.jpg)
![Page 11: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/11.jpg)
![Page 12: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/12.jpg)
![Page 13: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/13.jpg)
Only approved first line agents
Sorafenib
Lenvatinib
![Page 14: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/14.jpg)
![Page 15: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/15.jpg)
![Page 16: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/16.jpg)
![Page 17: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/17.jpg)
![Page 18: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/18.jpg)
Regorafenib
![Page 19: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/19.jpg)
![Page 20: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/20.jpg)
![Page 21: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/21.jpg)
Cabozantinib
![Page 22: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/22.jpg)
![Page 23: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/23.jpg)
![Page 24: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/24.jpg)
![Page 25: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/25.jpg)
Ramucirumab
![Page 26: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/26.jpg)
![Page 27: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/27.jpg)
![Page 28: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/28.jpg)
![Page 29: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/29.jpg)
![Page 30: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/30.jpg)
![Page 31: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/31.jpg)
Nivolumab
![Page 32: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/32.jpg)
![Page 33: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/33.jpg)
![Page 34: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/34.jpg)
![Page 35: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/35.jpg)
![Page 36: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/36.jpg)
![Page 37: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/37.jpg)
![Page 38: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/38.jpg)
![Page 39: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/39.jpg)
Multiple combination trials are ongooing
Durvalumab+ Tremelimumab
Nivolumab+ Ipilimumab/Cabozantinib
Lenvatinib+Pembrolizumab
Atezolizumab+ Bevacizumab
Nivolumab+ Sorafenib
![Page 40: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/40.jpg)
![Page 41: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/41.jpg)
![Page 42: GEORGE THERAPONDOS, MB CHB, FRCPC, MPH TRANSPLANT … · From 2008 through 2017 Multiple First-Line Trial Faill/rpg.rðlj Multiple agents failed to show superiority over sorafenib](https://reader034.vdocuments.site/reader034/viewer/2022050215/5f612a9b2313d939a4692825/html5/thumbnails/42.jpg)
Take home points
1) Rapidly evolving field
2) Choice of treatment for advanced HCC
TKIs
Immunotherapy
3)
First line= Sorafenib/Lenvatinib
Second line= multiple agents
Oncology involvement essential